Specific RNA structures control numerous metabolic processes that impact human health, and yet efforts to target RNA structures de novo have been limited. In eukaryotes, the self-splicing group II intron is a mitochondrial RNA tertiary structure that is absent in vertebrates but essential for respiration in plants, fungi and yeast. Here we show that this RNA can be targeted through a process of high-throughput in vitro screening, SAR and lead optimization, resulting in high-affinity compounds that specifically inhibit group IIB intron splicing in vitro and in vivo and lack toxicity in human cells. The compounds are potent growth inhibitors of the pathogen Candida parapsilosis, displaying antifungal activity comparable to that of amphotericin B. These studies demonstrate that RNA tertiary structures can be successfully targeted de novo, resulting in pharmacologically valuable compounds. K i = 251 ± 31 µM MIC: > 128 µg/ml IC 50 HEK-293 > 64 µg/ml K i = 5.8 ± 0.2 µM MIC: 8 µg/ml IC 50 HEK-293 = 23 ± 2 µg/ml K i = 0.36 ± 0.02 µM MIC: 2-4 µg/ml IC 50 HEK-293 > 64 µg/ml K i = 2.1 ± 0.2 µM MIC: 2-4 µg/ml IC 50 HEK-293 > 128 µg/ml K i = 1.94 ± 0.02 µM MIC: 16 µg/ml IC 50 HEK-293 = 1.3 ± 0.3 µg/ml K i = 2.1 ± 0.6 µM MIC: 16 µg/ml IC 50 HEK-293 = 34 ± 5 µg/ml
I t is becoming increasingly clear that large, highly structured RNA molecules are essential for most metabolic functions. In theory, RNA molecules present novel targets for drug discovery, but, with the exception of bacterial riboswitch inhibitors 1 , small-molecule inhibitors of RNA tertiary structures have not been successfully identified using the high-throughput screening and classical medicinal chemistry campaigns that have yielded most protein inhibitors. There are, to our knowledge, no new classes of antimicrobial compounds that target RNA and none that are designed to target eukaryotic pathogens. Though most inhibitors operate at the protein level, small molecules that target specific RNA structures can potentially modulate gene expression through a diversity of mechanisms, representing a powerful orthogonal strategy for the treatment of disease.
Previous studies on bacterial riboswitches have demonstrated that folded RNA molecules often bind small molecules such as metabolites with high affinity, and these ligands have been optimized in efforts to develop new antibiotics [1] [2] [3] [4] [5] [6] [7] . Likewise, group I introns and HIV-1 TAR RNA are known to bind small molecules [8] [9] [10] [11] . Indeed, antibacterial compounds have long been known to target ribosomal RNA 12, 13 , and given the availability of high-resolution structural data, these have been the subject of continuing optimization 14, 15 . There has also been a growing interest in understanding structural and physicochemical properties of small molecules that selectively bind RNA motifs 16, 17 . Though these studies provide important precedents, they were conducted on RNA molecules with known small-molecule ligands. De novo RNA targeting efforts by HTS and other methods have been limited, and they have focused primarily on small RNA secondary structural elements, such as junctions, miRNAs, RNA hairpins from triplet repeat diseases and stem-loops in viral RNA genomes 11, [18] [19] [20] [21] [22] [23] [24] . It would be ideal to identify small molecules that selectively bind RNA tertiary structures, as these more complex RNA motifs provide a route to specific molecular recognition, and they are often found in biomolecules of high medical relevance.
To accomplish this goal, we have focused on RNA targets within pathogenic yeasts, as these organisms have become increasingly problematic, particularly for patients with compromised immune systems such as recipients of implanted devices, neonatal patients, and cancer patients 25 . For example, there has been a marked increase in pathologies associated with non-albican strains, particularly C. parapsilosis 26 . The availability of potent antifungals that lack toxicity in mammals is a major unmet medical need and is of value for industrial and agricultural applications. The development of new antifungals is difficult as eukaryotes, fungi and yeast cells have enzymes and biochemical pathways that are similar to those of humans. However, fungal RNA metabolism differs substantially, thereby providing a potential route toward new therapeutics 27 .
To meet these challenges, we set out to identify small-molecule inhibitors of group II introns, which are large self-splicing ribozymes that are found in the mitochondrial genomes of plants, fungi, and yeast, but are not present in mammals. These autocatalytic RNA molecules adopt an elaborate tertiary structure that has been crystallographically characterized and contains an active site for RNA cleavage and ligation, as well as solvent-accessible pockets for potential inhibitor binding 28, 29 . In yeasts such as Saccharomyces cerevisiae and the pathogen C. parapsilosis, group II introns are found within genes that are essential for respiration, such as cytochrome oxidase subunit genes of the mitochondria 30, 31 . Importantly, respiration is essential for pathogenic yeast to differentiate into biofilms, which colonize medical implant surfaces, are relatively resistant to antifungals, and contribute to pathogenic virulence 27, 31, 32 . Thus, based on the complexity of their structures, and their essential role in fungal metabolism, group II introns represent outstanding targets for the development of highly specific antifungal agents.
Results
High-throughput screening. To identify group II intron splicing inhibitors, we developed a sensitive, high-throughput fluorescence assay for monitoring ribozyme activity of the well-characterized ai5γ group II intron from S. cerevisiae (Supplementary Figs. 1a and 2; Supplementary Table 1 ; Fig. 1a ). The self-splicing ai5γ group II intron was transformed into a multiple-turnover ribozyme by removing the flanking exons and consolidating catalytic domains to create the D135 ribozyme, which efficiently and specifically catalyzes cleavage of RNA 'substrate' oligonucleotides that contain sequences of the original 5′ splice site 33 . The RNA substrate for the screening assay was an oligonucleotide containing the last 17 nucleotides of the 5′ exon (which encompasses the 'intron binding sequences' that base pair with intron domain 1) and the first two nucleotides of the intron (substrate 17/2 DL, Supplementary  Fig. 2a) . A fluorophore and a fluorescence quencher were conjugated at positions on opposite sides of the scissile linkage so that fluorescence is observed when the oligonucleotide substrate is cleaved by the ribozyme ( Supplementary Fig. 2b ,c).
Using this assay for ribozyme activity, we screened a curated library of 10,000 compounds (see Methods) and identified 16 reproducible hits, some of which shared common structural elements that suggested a shared mechanism of action ( Supplementary  Fig. 2d ). We then analyzed a series of commercially available derivatives of the major hits to identify more suitable scaffolds for further optimization. The most potent scaffold identified during this phase of the study was compound 1 , which exhibited an IC 50 of 2 μ M (Supplementary Table 2 ). It was used as a starting point for the design of additional compounds that were used to define structure-activity relationships (SAR) and to optimize potency (Supplementary Table 2 ).
In vitro SAR and optimization of potency. To carry out the SAR studies in vitro, we complemented the primary fluorimetric assay with a robust secondary radioanalytic self-splicing assay of the precursor RNA containing the full-length ai5γ intron and short exons, which enabled the determination of K i values for all compounds of interest ( Fig. 1b ; Supplementary Fig. 3a -c; Supplementary Table 2 ).
As part of an initial strategy to optimize the early leads, a series of compounds was selected to determine the critical structural components required for activity, i.e., the pharmacophore. Three regions of compound 1 (A, B and C) were defined, and substituents in these sections of the molecule were evaluated for their effect on inhibition ( Fig. 2 ). In region A, replacing any of the hydroxyl groups with hydrogen or methoxy or boronic acid substituents (compounds 2 -5 , Supplementary Table 2 ) resulted in nearly complete loss of activity. Notably, when the trihydroxyl was replaced with a dihydroxyl catechol moiety, the molecule was inactivated both in vitro and in vivo (2 , Supplementary Table 2 ), indicating that the presence of the catechol motif by itself cannot explain reactivity of the group II intron inhibitors, unlike certain classes of promiscuous molecules that are collectively classified as 'PAINS' compounds.
In contrast, each of the hydroxyl groups in region C could be removed or replaced with halogen atoms without significant loss of function (compounds 6 -8 , Fig. 2 ; Supplementary Table 2 ). To minimize any risk of reactivity from the α ,β -unsaturated ketone, we replaced the 2-benzylidenebenzofuran-3(2H)-one moiety with a more chemically and metabolically stable benzofuran-2-yl(phenyl) methanone (region B). This more drug-like molecular template resulted in a two-fold increase in in vitro potency compared to the parental molecule 7 (compound 9 , Fig. 2 ; Supplementary Table 2 ). Other attempts to introduce changes in this region (for example, amide or thiazole derivatives) resulted in a substantial loss of activity (compounds 10 and 11 , Supplementary Table 2 ). The fact that potency was sensitive to certain modifications in region B, and in distal parts of region C (Supplementary Table 2 ), indicates that inhibitory activity is not solely attributable to functional groups in region A.
With the new lead structure (compound 9 ) in hand, additional substituents were added to the benzofuran moiety to further develop the structure-activity relationship for the series. Introductions of a wide variety of substituents, including aryl, heteroaryl, amino or halogens at the 5′ or 6′ positions were all generally tolerated (compounds 8 , 12 , 13 and 14 -19 ; Fig. 2 ; Supplementary Fig. 3c ; Supplementary Table 2 ). Notably, our data suggest that adding large substituents or positively charged residues to region C can increase inhibitory activity (lower the K i ) of the respective compounds ( Fig. 2 Table 2 ).
Reversibility of inhibitor binding to the intron was established using pulse-chase dilution experiments ( Supplementary Fig. 3d , see Methods). The clear reactivity patterns evident from this SAR analysis, together with facile reversibility of compound binding and inhibition, are consistent with selective behavior.
Inhibition of group II splicing in S. cerevisiae in vivo.
It was important to determine whether compounds that disrupt splicing of the ai5γ intron in vitro can also inhibit splicing of the intron in vivo. The ai5γ group II intron interrupts a gene encoding the first subunit of the cytochrome oxidase (COX1) in S. cerevisiae, and respiratorydeficient petite colonies are therefore formed when ai5γ intron splicing is disrupted. These colonies cannot grow on nonfermentable carbon sources like glycerol, but they exhibit growth on glucose 30 . To determine whether our inhibitory compounds might induce a respiratory defect, we compared the growth of S. cerevisiae in both YPD and YPGE media in the presence of a panel of inhibitors. We found that growth of S. cerevisiae in the presence of inhibitory small molecules is inhibited in glycerol/ethanol medium (YPGE), but not in glucose medium (YPD) ( Supplementary Table 3 ), which is consistent with the expected respiratory defect.
To analyze whether the growth defect observed in the presence of inhibitor is specifically due to defective splicing of the ai5γ intron, we tested whether the compounds inhibited growth of an 'intronless strain' , which contains an intact COX1 subunit gene from which the intron has been removed, thereby obviating the requirement for splicing 34 . We observed a clear difference in growth in between the intronless strain and the wild-type strain in the presence of compound 18 , revealing that the intronless strain is much more resistant to compound 18 in YPGE medium ( Fig. 3a ; Supplementary Fig. 4a ). This behavior is consistent with specific inhibition of the ai5γ intron in vivo. That said, growth of the intronless strain is somewhat slower in the presence of inhibitor, suggesting that 18 may cause certain off-target effects.
To directly monitor the effect of our most potent compounds on group II intron splicing in vivo, we developed a qRT-PCR assay for monitoring the splicing of the ai5γ intron in S. cerevisiae in the presence of small molecules. We found that our most potent compounds cause a severe splicing defect in vivo, which is evident from substantial accumulation of precursor RNA molecules containing the 5′ -exon-intron junction ( Fig. 3b ; Supplementary Fig. 4b ). Importantly, unspliced COX1 transcripts are targeted for rapid degradation in cells 35 , and thus the direct observation of substantial precursor accumulation suggests a considerable effect on splicing. Taken together, our results in cells demonstrate that the highest affinity compounds specifically target the ai5γ intron in vivo, selectively disrupting splicing of the COX1 gene and thereby reducing yeast growth.
Selectivity of the group II intron inhibitors.
Although the SAR, reversibility analysis and gene specificity of the compounds are consistent with selectivity, it was important to determine whether the compounds can also bind other highly structured RNA molecules and other RNA splicing systems. In addition, we wondered whether activity requires the fully folded group II intron RNA tertiary structure or if individual intron domains can bind the inhibitors with high affinity. To this end, we monitored inhibitory activity of one of the most promising compounds (19 ) in the presence of a large excess of various RNAs, including separate ai5γ intron domains D1, D3, D56, the U2-U6 snRNA stem-loop (analogous to group II intron D5) and yeast tRNA Phe ( Supplementary Fig. 1 , see Methods). The latter was an important control, because tRNA molecules possess many archetypal elements of RNA tertiary structure such as kissing loops involving canonical and noncanonical base pairs, coaxially stacked helices, base triples and U-turn motifs, which make them commonly used specificity controls for RNA targeting 36 . However, we observe that none of these RNAs, presented in a 1,000-fold excess relative to intron RNA (2 nM), affect the inhibitory activity of compound 19 (Fig. 4a ). The only RNA that competed with radiolabeled SE group II intron RNA for binding of 19 was the same unlabeled group IIB intron RNA added in excess (Fig. 4a) .
To evaluate inhibition of the other two known RNA splicing systems (group I and spliceosome), we monitored splicing of the Azoarcus pre-tRNA (Ile) group I intron 37 in the presence of compound 19 . We observed that splicing of the Azoarcus intron is unaffected even at 100 μ M compound 19 (Fig. 4b ). In addition, we used qRT-PCR to monitor inhibition of group I intron and spliceosomal splicing in S. cerevisiae in vivo. Consistent with our previous results, we found that the inhibitors only affect splicing of the yeast ai5γ group II intron (Fig. 3b ). Spliceosomal processing, group I intron splicing and even splicing of group II introns from subclasses that differ from subclass IIB are unaffected by the small-molecule inhibitors. These results are consistent with the in vitro results and suggest that the inhibitors bind selectively to group IIB introns. Our data also indicate that the inhibitors bind tertiary structural elements formed by the entire intron and not individual intronic domains.
Small-molecule growth inhibition of C. parapsilosis. The yeast pathogen C. parapsilosis contains a single group IIB intron in its COX1 gene 38 . The active site of this intron (D5) is almost identical to that of the ai5γ intron ( Supplementary Fig. 1b ), suggesting that compounds that inhibit the S. cerevisiae ai5γ intron may also inhibit splicing by the group II intron in C. parapsilosis. To evaluate efficacy of the compounds against this pathogen, we measured the minimum inhibitory concentrations (MIC values) required for growth inhibition of C. parapsilosis. We observed that the high-affinity ai5γ intron inhibitors significantly reduce the growth of C. parapsilosis ( Fig. 2; Supplementary Table 2 ). Correlations between IC 50 , K i and MIC values suggest that these compounds employ the same mechanism of action both in vitro and in vivo ( Fig. 2 ; Supplementary  Table 2 ). Although many of the highest affinity compounds displayed strong MIC values, compounds 18 (K i = 2.1 ± 0.2 µ M) and 19 (K i = 0.36 ± 0.02 μ M) were particularly notable because their MIC values (2-4 μ g/ml) are comparable to that of amphotericin B, which is still commonly used for acute C. parapsilosis infection 39 (MIC is 0.5-1 μ g/ml; Fig. 2 ; Supplementary Table 2 ). Given their potency and antifungal effects, we have named compound 18 Intronistat A and compound 19 Intronistat B.
To directly monitor the behavior of the compounds in vivo, we used qRT-PCR to quantify levels of splicing for the C. parapsilosis COX1 precursor mRNA (which contains the group IIB intron) in the presence of Intronistat B and inactive compound 4 . We observed a moderate splicing defect caused by Intronistat B, as indicated by increased levels of unspliced C. parapsilosis COX1 relative to total; this effect was not observed in the presence of inactive compound 4 ( Supplementary Fig. 4c ). To determine whether inhibition is specific to yeast, we evaluated toxicity of the most potent compounds in human cells, determining the IC 50 for inhibition of HEK-293T cells ( Fig. 2; Supplementary Fig. 5 ; Supplementary  Table 2 ). Although some of the compounds are broadly toxic to all eukaryotic cells tested, our most potent compounds, including Intronistat A and Intronistat B, did not show toxicity in human cells after 24 h incubation ( Fig. 2; Supplementary Fig. 5a ; Supplementary Table 2 ). Even after 72 h of incubation, Intronistat B had only mild effects on cell viability ( Supplementary Fig. 5b ), suggesting that this compound specifically targets yeast strains that contain group II introns in an essential gene and that it lacks cross-reactivity with the nuclear spliceosome, or other targets, in yeast and humans.
Discussion
In this study, we have demonstrated that the tertiary structure of a large, complex RNA molecule can be targeted de novo and that high-affinity compounds can be identified using classical methods for developing pharmacologically active compounds. The success of this study implies that high-complexity RNA tertiary structures, such as those found in viral genomes, in the untranslated regions of human mRNAs, pre-miRNA clusters, long intergenic noncoding RNAs and other RNAs essential for the regulation of gene expression, can potentially be targeted with specific, high-affinity small molecules to regulate their function.
An equally significant aspect of this project was the experimental approach used for RNA targeting. Most recent examples of RNA targeting by small molecules involve the use of rational drug design or the serendipitous discovery of natural products 20, 40, 41 . However, in this example, we used a classical method that has been refined through decades of investigations aimed at identifying inhibitors of regulatory proteins such as enzymes and receptor complexes. Indeed, we used the primary approach that pharmaceutical companies employ for drug design and optimization. Specifically, we created a high-throughput assay to screen compound libraries for inhibitory activity against an RNA molecule, identified hits, conducted SAR and then optimized a scaffold to generate potent inhibitors. We then demonstrated target specificity in vitro and in vivo using multiple orthogonal approaches. The success of this approach is significant for two reasons, particularly given the burgeoning interest in 'drugging RNA' . First, it demonstrates that the determinants for RNA recognition are sufficiently similar to those of proteins with existing libraries, and the same strategies can be employed for the identification of high-affinity RNA ligands. Second, it demonstrates that de novo targeting of large, complex RNA molecules can readily be accomplished using methods that are well established, and that 'reinventing the wheel' will not necessarily be required to identify inhibitors to bioactive RNA molecules. This is important, not least because it makes RNA targeting accessible to a large population of seasoned medicinal chemistry investigators who have much to contribute in this area of research.
The most potent inhibitors that we identified contain a gallate moiety, which is notable because related polyphenolic compounds, such as catechols, are sometimes found in promiscuous PAINS compounds 42, 43 . Although the presence of a gallate or catechol moiety necessitates caution, it should not disqualify a compound scaffold, because catechol reactivity is highly dependent on the architecture of the surrounding molecule 44 . Selectivity and appropriate behavior of such molecules must be established through rigorous SAR, reversibility, binding selectivity, cytotoxicity and other applicable methods, as in this study. Although caution is appropriate, recent studies demonstrate that more than 90% of small molecules that are flagged in automated PAINS screens (such as FAF-drugs3) are well-behaved compounds that have a low hit rate in conventional α -screen assays 44, 45 . Indeed, there is considerable recent concern that valuable bioactive compounds are being removed from the pool of informative chemical space by PAINS screens. This is a particularly serious problem in the development of RNA ligands, as the chemical space for RNA recognition is not well understood, and what is known from studies of RNA binding to macromolecules suggests that base stacking and hydrogen bonding, particularly to hydroxyls, drives tight binding 17, 46 . For these reasons, the gallate moiety in our group II intron inhibitors may be representative of a useful RNA binding motif, but its inclusion was necessarily accompanied by extensive selectivity analysis.
Finally, this study is significant because of its practical applications. Having shown that group II introns can be targeted with small molecules, we used the resulting compounds to inhibit the growth of yeast pathogens that uniquely depend on group II introns for metabolic function. Indeed, the best inhibitors we identified in this study have MIC values (~2 μ g/ml) comparable to that of amphotericin B (0.5-1 μ g/ml), which is a drug that is still used to treat severe fungal infections despite serious side effects 39 . Consistent with the lack of group II introns in vertebrate animals, our most potent inhibitor, Intronistat B, is not toxic in mammalian cells and does not influence spliceosomal RNA processing, suggesting that this molecule has potential for further development as an antifungal therapeutic. MIC values for C. parapsilosis are in good agreement with in vitro K i values for the S. cerevisiae ai5γ intron, indicating that the inhibitors function similarly in different yeast species that contain group II introns, suggesting a route for broad-spectrum fungal inhibitors. Given the unique RNA metabolism of plants, fungi and yeast, our results demonstrate that RNA targeting may provide a much needed approach for developing therapeutics against eukaryotic pathogens.
Given the vast number of physiologically important RNA tertiary structures that control gene expression in all domains of life, the ability to regulate RNA function with small molecules represents a new frontier in molecular medicine. Here we present a discovery pipeline for targeting RNA tertiary structures de novo and we demonstrate the pharmacological utility of small-molecule modulators by using them to specifically inhibit self-splicing group II introns, thereby disrupting the growth of pathogenic yeast. This demonstrates that RNA tertiary structures are attractive, accessible targets for the development of new probes and therapeutics.
Online content
Any methods, additional references, Nature Research reporting summaries, source data, statements of data availability and associated accession codes are available at https://doi.org/10.1038/ s41589-018-0142-0. The RNA was eluted in 50 μ l of RNase/DNase-free water (Thermo Fisher), followed by DNase treatment with RQ1 DNase (Promega), for 1 h at 37 °C. Then, it was mixed with 6 μ l of 3 M NaOAc and precipitated with 75% EtOH at − 20 °C overnight. The RNA was then reverse transcribed with SuperScript III (Thermo Fisher) following the manufacturer's recommendations with 200 ng Random Hexamer Primers (Thermo Fisher) and 40U RNasin (Thermo Fisher) in a 20μ l reaction. After reverse transcription, RNA was degraded by addition of 2 N NaOH (2 μ l) and incubation at 95 °C for 5 min. After cooling on ice for 5 min, 2 μ l of 1 M HCl and 2 μ l of 3 M NaOAc were added to the reaction mixture, and cDNA was precipitated with 75% EtOH at − 20 °C for 30 min and resuspended in RNase/ DNase-free water. The cDNA levels were quantified with real-time PCR using LightCycler 480 SYBR Green I (Roche) and a CFX384 Real-Time PCR Detection System (Bio-Rad) in triplicate with independent samples. Relative levels of indicated RNA species from different conditions were normalized according to the Δ Δ C T method via the following equation 56 :
test compound (C 1 total or unspliced C 1 or 1)
The mean and s.e.m. of 2 −ΔΔCT is reported for each sample from four independent replicates. The following primer sets were used to amplify indicated targets: ACT1: TCGAACAAGAAATGCAAACCG, GGCAGATTCCAAACCCAAAAC; PGK1: TGTCTTGGCTTCTCACTTGG, TTCAACTTCTGGACCGACAC; total COX1: TGGTATGCCTAGAAGAATTCCTG, AGAATAATGATAATAGTGCAATGAATGAAC; COX1 unspliced aI1: GGCAGGAACAGCAATGTCTT, TGCTAGACGCATCAACGAAA; COX1 unspliced aI2: TTAGTAGTTGGTCATGCTGTATT, CCCAACTGGGTAAGCCATA; COX1 unspliced aI5α: TGCTATGGCTTCAATTGGATT, TTTTATTTTTATTTTTATCCTTGCTAAAGGG; COX1 unspliced aI5β: TCACAATGGGTGGTTTAACTGG, ATTTTAGTGAATTTTAAGCACGACAC; COX1 unspliced aI5γ: CTTACTACGTGGTGGGACATT, GTCATTACAGCTTAGCATATTTATGT; total YRA1: AAACGCAGTCGCTAGAGTTG, CCTGCTTAATGTCCCTTGGC; unspliced YRA1: GTCAAGGTCAACGTCGAAGG, CACGAGACGATGCGAGTAAC; total MTR2: ACACAACATGCCCTAACAGG, TTGGGTCGATTTCTGTTCCC; unspliced MTR2: GGATGCGCAAACGCATAG, TCTTCGTAAATGTGGCCGTT.
In the course of analysis, no RT control samples displayed minimal signal, indicating that amplicons had been generated from cDNA and not genomic DNA, and gel electrophoresis confirmed specific amplification of the intended amplicon. 31 . Therefore, a C. parapsilosis growth defect in RPMI-1640 medium would be expected in the presence of the group II intron splicing inhibitors. The final concentration range of the assay was 0.25-128 μ g/ml for test compounds and 0.0625-32 μ g/ml for amphotericin B and itraconazole. The final concentration of DMSO was 1%. The assay plate was incubated at 35 °C or 37 °C and visually analyzed for turbidity after 24 and 48 h of incubation. The lowest compound concentration at which no growth was apparent is reported as the MIC. All experiments were performed in triplicate.
Analysis of group II intron splicing in
Cytotoxicity in HEK-293T cells. HEK-293T cells were cultured in DMEM (Gibco) supplemented with 10% Fetal Bovine Serum (FBS, Gibco) and 100 U/ml of Penicillin-Streptomycin (Gibco) at 37 °C and 5% CO 2 . For the cytotoxicity experiments, cells were aliquotted into black 96-well plates with a clear bottom (Corning 3603) at a concentration of 10,000 cells per well. The cells were grown at 37 °C, 5% CO 2 for 5-6 h, then the medium was replaced with the same medium without FBS and cells were grown at 37 °C, 5% CO 2 for 24 h. Freshly prepared stock solutions of test compounds (12.8 mg/ml in DMSO) were serially diluted 1:2 with DMSO into the first 11 successive wells of a 12-well row on a 96-well plate as described above. Well 12 was used as a growth control (no compound). After dilution, 1 μ l from each well of the compound plate was added to the plate containing cells (the assay plate), and cells were incubated at 37 °C, 5% CO 2 for another 24 or 72 h. After incubation, cell viability was determined using the luminescent Cell Titer Glo cell viability assay (Promega), in which 100 μ l of the assay reagent was added to each well of the assay plate. After gentle shaking for 7-10 min, the plates were analyzed on a Synergy H1 plate reader (BioTek). Luminescence was plotted against the compound concentration and IC 50 values were determined by fitting the data to a 4-parameter logistic function c + (d -c)/(1 + (x/a) b ), where a is the IC 50 , b is the slope parameter, c is the minimum response and d is the maximum response. Experiments were replicated four times for compounds 2 , 3 , 5 , 7 , 9 , 11 , 12 , 15 , 18 and 19 , three  times for compounds 1 , 6 , 8 , 10 , 13 , 14 , 16 and 17 , and twice for compound 4 to ensure reproducibility. 6 , 8 , 10 , 13 , 14 , 16 and 17 .
The following reported data represent average of n = 4 independent experiments: K i for compound 3 , Δ Δ C T values obtained from qRT-PCR analysis of group II intron splicing in S. cerevisiae, IC 50 values for cytotoxicity in HEK-293T cells for compounds 2 , 3 , 5 , 7 , 9 , 11 , 12 , 15 , 18 and 19 .
The following experiments were repeated twice to ensure reproducibility: test of reversibility of compound binding, S. cerevisiae growth assays, cytotoxicity of compound 4 in HEK-293T cells, K i determination for compounds 1 , 2 , 4 -13 and 15 -17 .
All values are reported as mean ± s.e.m.
Reporting Summary. Further information on research design is available in the Nature Research Reporting Summary linked to this article.
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